Connect with us

Press Release

FinHarbor Launches AI Co-Investigator for AML

Published

on

Nicosia, Cyprus, July 20th, 2026, FinanceWire

A self-hosted LLM connected to the platform’s ledger, KYC/KYB, KYT, and audit trail takes over the routine layer of AML investigations – while every decision with regulatory consequences stays with a human

FinHarbor, a technical platform provider for launching compliant, modular financial products, has announced the launch of its AI Act-ready compliance module – an AI co-investigator that works on top of the platform’s existing compliance stack and is deployed entirely inside the client’s own infrastructure.

The timing matters. On 2 August 2026, the EU AI Act’s transparency obligations take effect for customer-facing AI systems, while the recently adopted simplification package moved the high-risk requirements to December 2027 – a preparation window, not an amnesty. FinHarbor’s answer is a module designed around the Act’s logic from day one: documented, supervised, and architecturally incapable of acting alone.

The problem: compliance teams drowning in false alarms

The economics of AML operations are well documented. According to Google Cloud, more than 95% of alerts generated by rules-based AML systems turn out to be false positives at first review, and roughly 98% never result in a suspicious activity report. Compliance teams at growing platforms spend the bulk of their time reconstructing cases from disconnected tools rather than investigating genuine risk.

The industry results from applying AI to this layer are equally documented. HSBC, working with Google Cloud, cut alert volumes by more than 60% while identifying two to four times more genuinely suspicious activity. In a Coforge deployment at a leading US bank, an AI-powered alert optimization framework reduced false positives by 70% and improved fraud detection rates by 35%.

What the module does

FinHarbor’s co-investigator operates across the platform’s unified ledger, KYC/KYB, KYT, transaction monitoring, and append-only audit trail. In practice, it:

  • Pulls client and transaction data on demand. An analyst asks a question in plain language; the module queries the platform’s databases directly – no SQL, no waiting for a data team.
  • Clears the routine layer of AML alerts. Recurring false positives are classified and closed with documented reasoning, leaving human analysts only the cases that warrant judgment.
  • Assembles the full case. Transactions, counterparties, KYC/KYB history, on-chain trail from KYT, sanctions and PEP screening results – linked into a single investigation profile instead of a manual reconstruction across tools.
  • Drafts SAR/STR narratives. The module prepares the regulatory filing in the accepted format; the compliance officer reviews, edits, and signs.
  • Prioritizes the investigation queue by risk score, so the highest-risk cases surface first.
  • Answers regulator and auditor requests with an export from the unified audit trail rather than a manual evidence-gathering exercise.

A co-investigator, not an autopilot

The module’s operating principle is built into its architecture: AI investigates, humans decide. It never files a SAR, blocks an account, or takes any action with regulatory consequences on its own – every such step requires a human signature. This human oversight model, together with system documentation and model risk management, is how the module addresses the AI Act’s high-risk regime, while built-in disclosure ensures that in any chat-based scenario users always know they are interacting with AI.

The same architecture covers DORA: the append-only audit log meets third-party oversight requirements and streams directly into the client’s SIEM.

Deployed inside the perimeter, not in someone else’s cloud

The module runs as a self-hosted LLM within the client’s own environment, connected to the platform’s modules and databases through an MCP server behind the client’s authentication. Setup means scoping access – which modules and accounts the model can read, under which API keys and limits – selecting the model, and configuring redaction rules for regulated fields. Documentation and human oversight are part of the deployment, not an add-on.

This is also why the module’s relevance extends well beyond the EU. The core design principle – regulated data never leaves the client’s perimeter – answers the same requirement under GDPR, UK GDPR, Switzerland’s revFADP, Brazil’s LGPD, and Saudi Arabia’s PDPL. The AI Act is the entry point, not the boundary.

“Compliance teams don’t need another dashboard – they need the routine taken off their hands without giving up control,” said Ilya Podoynitsyn, CEO of FinHarbor. “Our co-investigator reads the same ledger, the same KYC files, the same on-chain data our platform already maintains, and does the legwork: assembles the case, drafts the narrative, documents every step. But nothing that matters to a regulator happens without a human signature. That’s not a limitation we accepted – it’s the design principle we started from.”

The module is currently running in pilots on several client projects. The underlying infrastructure – MCP and self-hosted LLM deployment within the client perimeter – is already part of the FinHarbor platform and publicly documented. The module is delivered as part of the platform, with commercial terms defined per deployment.

About FinHarbor

FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond.

Learn more: www.finharbor.com

Contact

Maxim Yakushev
FinHarbor
press@finharbor.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Interest in Indoor Playgrounds Jumps 44% in Philadelphia as November Arrives

Published

on

Searches for indoor playgrounds climb as soon as the cold arrives, a pattern Playspace by Kidology also sees with families at its two locations.

Philadelphia, Pennsylvania, United States, 5th Nov 2026 — Every year, Playspace by Kidology sees families head indoors as the cold arrives. While reviewing search trends as part of its seasonal marketing research, the team found that the same shift shows up clearly online. According to search data from Ahrefs, a search research platform, searches for “indoor playground philadelphia” run 37% above their yearly average in November and keep climbing through the season: 19% above average in December, 66% above in January and still 14% to 17% above in February and March. From April to September, the same searches fall 12% to 36% below average.

Interest in Indoor Playgrounds Jumps 44% in Philadelphia as November Arrives

Google Trends shows the same pattern over a longer period. Across the past five years in the Philadelphia area, interest in “indoor playground” has been about 44% higher in November than in October, and it has reached its highest point between December and February every winter.

The timing follows the weather. Average highs in Philadelphia drop from about 56°F in November to about 40°F in January, the coldest month of the year, with average lows in the mid-20s. The pattern is national too: searches for “indoor playground near me” average about 44,000 a month in the U.S. and reach their highest point in January, 27% above average.

“We see it every year at our own front door: as soon as the cold sets in, more families come in looking for somewhere warm where their little ones can climb, run and burn off energy,” said Luba Patlakh Kaplun, founder of Kidology. “When we looked at the search data, it showed the same thing, and it starts earlier than many people think. Winter is long in Philadelphia, and for parents of toddlers and young kids, an indoor playground is one of the easiest ways to keep active play in the week, whatever the weather.”

What the numbers mean for Philadelphia families

  1. Winter planning starts in November, not January. Local searches for indoor playgrounds are already 37% above average in November. Families who line up their cold-weather outings now have a plan before the January peak.
  2. Birthday party venues are booked early. Nationally, searches for kids’ birthday party venues run 49% above average in November and 58% above in January, so winter and spring party dates go quickly.
  3. Indoor play isn’t only a winter thing. There is a second, smaller rise in summer: searches for indoor activities for kids are 30% above average in July, when the heat keeps families inside.

About Playspace by Kidology

Playspace by Kidology is an indoor playground for children from birth to 12, with locations in Northeast Philadelphia and Southampton, Bucks County. Kids climb rock walls, go down slides and play in sensory-friendly spaces. The playground is also available for birthday party rentals and play gift cards are available for the holidays.

For more information, visit kidologyplayspaces.com

Media Contact

Organization: Playspace by Kidology

Contact Person: Luba Patlakh Kaplun

Website: https://kidologyplayspaces.com/

Email: Send Email

Contact Number: +12153304116

Address: 928 Jaymor Rd c150, Southampton, PA 18966

Address 2: 2800 Southampton Rd, Philadelphia, PA 19154

City: Philadelphia

State: Pennsylvania

Country: United States

Release id: 50488

View source version on King Newswire:
Interest in Indoor Playgrounds Jumps 44% in Philadelphia as November Arrives

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Maylene Showcases Its Best-Selling Research Peptides with UK-Wide Delivery

Published

on

Research-use catalogue combines prefilled formats, clear product specifications and supporting documentation, with free delivery across the United Kingdom.

United Kingdom, 5th Nov 2026 – Maylene is putting the spotlight on its best-selling research peptide range, giving laboratory buyers access to an online catalogue backed by UK dispatch, clearly displayed pricing and available product documentation.

Maylene Showcases Its Best-Selling Research Peptides with UK-Wide Delivery

The Maylene platform brings together research peptides, individual compound listings and educational resources in one place. Visitors can explore available products, compare labelled strengths and review format and pack information before placing an order.

With free UK-wide delivery, Maylene offers a convenient purchasing option for laboratory buyers who value accessible product information and straightforward ordering. Its catalogue includes individual compounds, blends and bundles, allowing customers to browse different options according to their research requirements.

Featured Compounds Across the Maylene Range

Maylene’s featured selection includes BPC-157, GHK-Cu, retatrutide and compound blends, giving laboratory buyers a range of research-use options to explore. Each listing clearly presents the product name, labelled content, format and price, making it easier to compare specifications and review available supporting documentation before ordering.

This presentation gives customers a practical basis for comparison. Rather than relying on a product name alone, visitors can review the stated strength, check the selected pack and examine any supporting records available for that product.

For buyers exploring multiple options, dedicated collections make it easier to navigate the catalogue and move between individual listings. Product bundles are also presented separately, helping visitors distinguish a single item from a combined purchase.

Prefilled Research Formats in One Collection

The Maylene peptide pen collection brings together prefilled single-compound and blend products. Listings identify labelled content and pack quantities so laboratory buyers can compare available formats with greater clarity.

The distinction between individual content and total pack content is particularly useful when reviewing multipacks. A pack containing two pens has a different specification from a single pen carrying the same combined total. Maylene’s product information allows visitors to check those details before purchasing.

Blend listings also provide composition information, giving buyers a way to review the individual compounds within a product rather than relying only on its combined labelled strength.

All products in the collection are supplied for laboratory and research purposes only.

Product Documentation Available for Review

Alongside its catalogue, Maylene provides access to published laboratory reports where available. Customers can review these records and check whether the documentation corresponds to the product and strength they intend to purchase.

Maylene explains that published reports relate to the samples tested. They do not verify every batch in stock, and report coverage is not available for every product. Buyers should therefore check the documentation relevant to their exact item and contact the team where further clarification is needed.

Making these distinctions visible gives customers a more useful basis for evaluating product information. Labelled specifications, published records and batch details each serve a different purpose and should be considered together.

Free UK Delivery and Direct Support

Maylene offers free delivery across the United Kingdom, with products dispatched from the UK and tracking information provided after dispatch. International shipping is also available, with delivery details presented on the website.

Customers can review ordering information before completing a purchase, including their selected product, pack quantity and total. For questions about available documentation, product specifications or the ordering process, Maylene provides direct support through its listed contact channels.

This combination of UK fulfilment and accessible support gives laboratory buyers a clear route from browsing the catalogue to resolving product-specific enquiries.

Research Resources Beyond the Catalogue

Maylene’s website also features educational guides and compound information, providing additional context for visitors exploring its range. These resources sit alongside the commercial catalogue, allowing buyers to review background information while checking individual product specifications.

The platform brings together catalogue navigation, research reading and available documentation without changing the products’ stated purpose. Educational material does not establish suitability for human use or replace the assessments required for a laboratory’s own work.

Maylene invites laboratory buyers to explore its featured range, compare available formats and review the relevant product information before ordering.

About Maylene

Maylene supplies research-use products dispatched from the United Kingdom. Its online catalogue includes individual compounds, prefilled research pens, blends and bundles, supported by educational resources and available laboratory documentation. The company offers free UK delivery and international shipping options.

Research-Use Notice

All products sold by Maylene are intended solely for laboratory and research purposes. They are not intended for human or veterinary use, consumption or application. Product descriptions and educational resources do not constitute medical advice.

Media Contact

Organization: Maylene

Contact Person: Sam Aquino

Website: https://www.maylene.uk/

Email: Send Email

Country: United Kingdom

Release id: 50483

View source version on King Newswire:
Maylene Showcases Its Best-Selling Research Peptides with UK-Wide Delivery

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Together We Build Iraq Mayes Ali Hadi Al-Hassany’s Journey from the Laboratory to a Vision for Iraqi-Made Medicines

Published

on

From a land shaped by ancient civilisations, Iraqi researcher Mayes Ali Hadi Al-Hassany brings together pharmaceutical science, project management and technology. She has a clear goal for investors to get behind: building factories in Iraq that make medicines patients can trust and supply them to markets across the region.

Iraq, 5th Nov 2026 – Together We Build Iraq Mayes Ali Hadi Al-Hassany’s Journey from the Laboratory to a Vision for Iraqi-Made Medicines – Together, we build Iraq. Imagine a pharmacist in Amman or Dubai reaching for a box marked “Made in Iraq.” Behind that box are researchers who developed its formulation, technicians who mastered its production, and a laboratory that verified its quality before it left the factory. This is the scene Mayes Ali Hadi Al-Hassany wants to see become part of Iraq’s future.

Returning to the Classroom

Mayes Al-hassany began her career in pharmacy and went on to pursue research in pharmaceutical science and manufacturing. After gaining experience in the field, she stepped away from pharmacy practice for a time and returned to the classroom to study project management. She wanted to learn how to secure funding for a scientific idea, build the team to carry it out, and use promising laboratory results to make a case for manufacturing to investors.

She attended several international conferences, kept up with developments in Western pharmacy markets, and studied the business models of retailers such as Australia’s Chemist Warehouse, Britain’s Boots and Watsons. What caught her attention was the work behind the shelves. Even before a factory buys its first piece of equipment, demand, product availability and distribution can help determine which medicines are worth making and in what quantities.

From Pharmaceutical Research to the Factory Floor

Mayes Al-hassany completed a series of studies in pharmaceutical science and manufacturing and published her work internationally. Her research included developing a formulation for extended-release metformin tablets and comparing its drug-release profile with that of a reference product. She also studied the stability of amlodipine tablets under hot and humid conditions to understand how formulation and packaging affect the quality of the medicine during storage.

She discussed her work with academics and researchers from universities and research centres in several countries. Some of those who reviewed her studies and discussed them with her expressed admiration for her work. They saw her ability to connect laboratory questions with manufacturing challenges as a sign of what she could contribute to pharmaceutical science in the years ahead.

That connection shapes her vision for Iraqi manufacturing. She wants an Iraqi factory to begin with a carefully chosen product, a team that knows how to maintain its quality, and a system that can trace every batch. Once the factory demonstrates consistent quality and reliable supply, it can pursue registration and distribution in neighbouring markets in line with local requirements.

A Call to Iraqi Investors

Mayes Al-hassany’s message to investors is clear. Invest in pharmaceutical factories in Iraq and in the people who will run and improve them. A single production line backed by a sound feasibility study can give Iraqi researchers a place to put their knowledge to work at home, young technicians a chance to gain industrial experience, and patients access to locally made medicines they can trust.

For Mayes Al-hassany, pride in Iraq’s heritage finds expression in the path she has chosen. She wants to put her knowledge to work for others and bring the questions she learned to ask in the laboratory to the factory floor. When a box of Iraqi-made medicine reaches a pharmacy beyond the country’s borders, the achievement worth celebrating will be the work behind it: the people who turned scientific knowledge into a medicine someone could depend on.

Media Contact

Organization: HQearth

Contact Person: Mayes Ali Alhassany

Website: https://www.hqearth.org/

Email: Send Email

Country: Iraq

Release id: 50485

View source version on King Newswire:
Together We Build Iraq Mayes Ali Hadi Al-Hassany’s Journey from the Laboratory to a Vision for Iraqi-Made Medicines

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST